Adaptimmune is rolling out its T cell therapy Tecelra for synovial sarcoma, recording $1.2 million in sales since its approval in August 2024. Nevertheless, it is pausing development of two oncology assets to save money.Read More
Adaptimmune Raises ‘Substantial Doubt’ About Business Despite First-in-Class T Cell Therapy
